Home | Infections | Hepatitis


UCLA public health researchers go to church to promote hepatitis B screening

A team from the Fielding School of Public Health held small group discussions in more than 50 Los Angeles-area Korean churches ...

Study details microRNA’s role as a double agent during Hep C infection

In the battle between a cell and a virus, either side may resort to subterfuge. Molecular messages, which control the cellular machinery ...

WHO issues its first hepatitis B treatment guidelines

GENEVA - WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year – most of them in low- and middle-income countries. ... Full story

Finding Strengths — and Weaknesses — in Hepatitis C’s Armor

Study by Johns Hopkins researchers could boost vaccine development efforts ... Full story

Worldwide treatment of hepatitis C could be within sight at the right cost

A 12-week course of the new drug sofosbuvir in the US is priced at as much as $84,000 per person ... Full story

Berry scare: here’s what you need to know about hepatitis A

OPINION: School students in Victoria, South Australia, and Queensland are the latest group thought to have eaten frozen berries linked to hepatitis A, which has now infected 14 people nationally. All food-borne disease outbreaks are frightening, but the good news for this one is that hepatitis A is rarely life-threatening. ... Full story

Hepatitis C more prevalent than HIV/AIDS or Ebola yet lacks equal attention

Loyola’s HepNet study reveals high frequency of active infection and multiple risk factors in Ghana ... Full story

Reactivation of Hepatitis B Can Be Prevented and Treated During Immunosuppressive Drug Therapy

New American Gastroenterological Association Guidelines Provide Guidance on Managing the Clinical Problem ... Full story

Potential cure for hepatitis B enters phase 1/2a clinical trial

A new treatment developed by Walter and Eliza Hall Institute researchers to promote the cure of chronic hepatitis B virus (HBV) infection is now recruiting patients for a phase I/2a clinical trial. ... Full story

Simeprevir-Based Therapy Offers Patients in Developing Countries a Cost-Effective Alternative in Treatment of Hepatitis C

PHILADELPHIA — Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries. Further, simeprevir proved to be simpler for patients and had fewer adverse events. The complete study is now available online and is scheduled to publish in January 2015 in The Lancet Infectious Diseases. ... Full story

1 2 3 4 5 6 7 next total: 68 | displaying: 1 - 10